Guardant Health, Inc.
GH- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001576280
In the last 90 days, Guardant Health, Inc. insiders filed 1 open-market purchase and 14 sales; 626 institutions reported holding it in 13F filings for Q2 2026, worth $22.1B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysLast 90 days, $78.5K in total
- 1
- Insider sellsLast 90 days, $70.2M in total
- 14
- 13F holdersQ2 2026, +124 vs. previous quarter
- 626
- 13F valueReported value at the end of Q2 2026
- $22.1B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding GH, Q2 2026
1 superinvestor reports holding Guardant Health, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by Guardant Health, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)5:11 PM ET | Sep 15 | 2 days | Chudova DaryaChief Technology Officer | SSale | −7.74K | $178.00 | −$1.38M | −9.9%70.6K after | |
| Sep 17, 2026 (view filing)5:10 PM ET | Sep 16 | 1 day | Krognes Steve E.Director | SSale | −6.67K | $175.74 | −$1.17M | −45.8%7.91K after | 4 lots |
| Sep 17, 2026 (view filing)5:09 PM ET | Sep 16 | 1 day | Azar Alex M IIDirector | SSale | −826 | $175.00 | −$144.6K | −50.0%825 after | 10b5-1 |
| Sep 17, 2026 (view filing)5:09 PM ET | Sep 16 | 1 day | Tariq MusaDirector | SSale | −116 | $175.00 | −$20.3K | −1.0%11.4K after | 10b5-1 |
| Sep 14, 2026 (view filing)6:11 PM ET | Sep 11 | 3 days | Kalia KumudChief Information Officer | SSale | −4.00K | $158.05 | −$632.2K | −9.1%39.8K after | |
| Aug 24, 2026 (view filing)5:21 PM ET | Aug 21 | 3 days | Talasaz AmirAliCo-Chief Executive Officer | SSale | −37.5K | $169.16 | −$6.34M | −50.0%37.5K after | 3 lots |
| Aug 18, 2026 (view filing)6:14 PM ET | Aug 17 | 1 day | Tariq MusaDirector | SSale | −116 | $156.45 | −$18.1K | −1.0%11.3K after | 10b5-1 |
| Aug 13, 2026 (view filing)7:21 PM ET | Aug 12 | 1 day | Monroe Terilyn J.Chief People Officer | SSale | −46.3K | $165.12 | −$7.65M | −66.8%23.0K after | 5 lots |
| Aug 11, 2026 (view filing)6:22 PM ET | Aug 10 | 1 day | Freeman ChrisChief Commercial Officer | SSale | −63.6K | $169.58 | −$10.8M | −49.3%65.4K after | 4 lots |
| Aug 6, 2026 (view filing)5:06 PM ET | Aug 5 | 1 day | Hidalgo Medina ManuelDirector | SSale | −1.70K | $164.24 | −$279.2K | −27.2%4.56K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Guardant Health, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,622,935 | $1.23B | 0.02% | −3,930,824−34.0% | Reduced |
| Price T Rowe Associates Inc | 6,514,952 | $977.4M | 0.10% | −508,737−7.2% | Reduced |
| Vanguard Capital Management LLC | 5,755,857 | $863.6M | 0.02% | +131,677+2.3% | Added |
| FMR LLC | 5,488,272 | $846.6M | 0.04% | +1,372,191+33.3% | Added |
| Vanguard Portfolio Management LLC | 5,445,785 | $817.0M | 0.04% | −392,207−6.7% | Reduced |
| Invesco Ltd. | 4,429,755 | $664.6M | 0.05% | −516,714−10.4% | Reduced |
| Linden Advisors LP | – | $632.4M | 3.28% | – | – |
| Goldman Sachs Group Inc | 3,775,895 | $577.9M | 0.06% | −659,944−14.9% | Reduced |
| Two Sigma Investments, LP | 3,719,301 | $558.0M | 0.42% | −510,230−12.1% | Reduced |
| D. E. Shaw & Co., Inc. | 1,255,658 | $539.3M | 0.33% | +828,183+193.7% | Added |